You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pembrolizumab

Showing 51 - 75 of 1,067
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Carcinosarcoma, Uterine Carcinosarcoma Trial (Eribulin Mesylate, Pembrolizumab)

Not yet recruiting
  • Ovarian Carcinosarcoma
  • Uterine Carcinosarcoma
  • Eribulin Mesylate
  • Pembrolizumab
  • (no location specified)
Jan 31, 2023

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Washington (BXCL701, Pembrolizumab)

Not yet recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023

Metastatic Head Neck Cancer, Recurrent Head Neck Cancer Trial in Worldwide (Bempegaldesleukin, Pembrolizumab)

Terminated
Has Results
  • Metastatic Head and Neck Cancer
  • Recurrent Head and Neck Cancer
  • Omaha, Nebraska
  • +3 more
Dec 16, 2022

Soft Tissue Sarcoma Adult, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma Trial in Denmark, Norway, Sweden (Propranolol,

Recruiting
  • Soft Tissue Sarcoma Adult
  • +2 more
  • Aarhus, Denmark
  • +3 more
Jul 23, 2023

Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer Trial in Tampa (Pembrolizumab, Lenvatinib)

Active, not recruiting
  • Neuroendocrine Tumors
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 24, 2023

Undifferentiated Pleomorphic Sarcoma Trial in Iowa City (Palbociclib, Pembrolizumab)

Not yet recruiting
  • Undifferentiated Pleomorphic Sarcoma
  • Iowa City, Iowa
    University of Iowa Hospitals & Clinics
Nov 1, 2023

Human Immunodeficiency Virus Trial run by the CC (Placebo, Pembrolizumab)

Recruiting
  • Human Immunodeficiency Virus
  • Placebo
  • Pembrolizumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Small Cell Carcinoma, Hypercalcaemic Type, Ovarian Cancer Trial in Toronto (Pembrolizumab)

Active, not recruiting
  • Small Cell Carcinoma, Hypercalcaemic Type
  • Ovarian Cancer
  • Pembrolizumab
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Solid Tumor Trial (SKB264, Pembrolizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Dec 8, 2022

Advanced Non Small Cell Lung Cancer Trial run by the National Cancer Institute (NCI) (aerosolized aztreonam, aerosolized

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • aerosolized aztreonam
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Mar 28, 2023

Breast - Female, Male Breast Cancer Trial in Charlotte (Pembrolizumab, Paclitaxel)

Completed
Has Results
  • Breast - Female
  • Male Breast Cancer
  • Charlotte, North Carolina
    Levine Cancer Institute
Jan 25, 2023

Urothelial Carcinoma Trial (disitamab vedotin, pembrolizumab, gemcitabine)

Not yet recruiting
  • Urothelial Carcinoma
  • disitamab vedotin
  • +4 more
  • (no location specified)
Jun 9, 2023

Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin Trial in Tampa (Lenvatinib Oral

Recruiting
  • Merkel Cell Carcinoma
  • +2 more
  • Lenvatinib Oral Product
  • Pembrolizumab
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • pembrolizumab
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

Vulva Cancer, Vulva Tumor, Squamous Cell Cancer Trial (Pembrolizumab)

Not yet recruiting
  • Vulva Cancer
  • +2 more
  • Pembrolizumab
  • (no location specified)
Mar 7, 2023

Glioblastoma Trial run by the NCI (drug, biological, other)

Completed
  • Glioblastoma
  • Pembrolizumab
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 23, 2022

Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma Trial in Birmingham (M032, Pembrolizumab)

Recruiting
  • Glioblastoma Multiforme
  • +2 more
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 30, 2023

Prostate Cancer Metastatic Trial (Pembrolizumab, Carboplatin, Cabazitaxel)

Not yet recruiting
  • Prostate Cancer Metastatic
  • Pembrolizumab
  • +2 more
  • (no location specified)
Sep 29, 2022

Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer Trial in Austin, San Antonio, Fairfax (BDC-3042,

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Austin, Texas
  • +2 more
Sep 19, 2023

Recurrent Glioblastoma Trial in Houston (Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab)

Not yet recruiting
  • Recurrent Glioblastoma
  • Pembrolizumab
  • Exablate MRgFUS + neoadjuvant pembolizumab
  • Houston, Texas
    M D Anderson Cancer Center
May 18, 2023

Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma Trial (Pembrolizumab)

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • +2 more
  • Pembrolizumab
  • Indianapolis, Indiana
  • +1 more
Jan 12, 2023

Advanced Head and Neck Squamous Cell Carcinoma Trial (Pembrolizumab, MET-4, Placebo)

Not yet recruiting
  • Advanced Head and Neck Squamous Cell Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Feb 22, 2023

Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous

Recruiting
  • Oral Cavity Squamous Cell Carcinoma
  • Pembrolizumab
  • Guangzhou, Guangdong, China
    Liuxiqiang
Feb 1, 2023

Breast Cancer Trial in Los Angeles (Pembrolizumab, RT Boost)

Active, not recruiting
  • Breast Cancer
  • Pembrolizumab
  • RT Boost
  • Los Angeles, California
    Cedars-Sinai Medical Center
Dec 1, 2022

Non-squamous NSCLC Trial (biological, drug, dietary supplement)

Not yet recruiting
  • Non-squamous NSCLC
  • Pembrolizumab
  • +7 more
  • (no location specified)
Feb 20, 2023